Archive
Archive & Timeline
This page holds selected technical and program threads that expand the record without overloading the main hub.
Selected Threads
- RCAP — the original end goal: a Remote Control Artificial Pancreas incorporating intelligent interpretation and control
- C4i artificial pancreas design — an early control-system architecture later revisited in Philips Virtual Care Management-related work
- GlucoMESSENGER — messaging and alerting layer supporting remote diabetes workflows
- Virtual-CDE — remote educational and support model extending expert guidance beyond the clinic visit
- Virtual patient modeling — work tied to simulation and scenario thinking relevant to diabetes systems design
- Clinical pilots — type 1, type 2, pregnancy, school, social network, and population-health oriented studies
- healthimo — commercialization and telehealth operating layer extending the earlier Diabetech work
- Diabetes Housecall — remote follow-up care model pairing clinician visits with home-based telehealth support
- Connected device evolution — direct sensor integration, messaging meters, and later regulated clinical implementations
Working Timeline
- 2001 — founding vision, early designs, and prior-art-focused patent activity
- 2002 — system live; first patient in on December 19
- 2003 onward — broader pilots, reporting, remote support, and scale-up
- Mid/late 2000s — care-model expansion, social support, payer pilots, and commercialization paths
- 2010–2011 — Healthimo and Diabetes Housecall extend the work into a more formal telehealth commercialization layer
- Later years — connected meters, direct integration, AP-related architectures, and new narrative systems
Ultragenyx Pharmaceutical
Innovation Lab
Context
Clinical technology and operations organization supporting metabolic and rare-disease programs.
Evidence
Innovation Lab (~54-person team); Phase II–III and Phase IV support; global pivotal Phase III work linked to Dojolvi.
Role
Established and led the Innovation Lab; built the operating capability for product, engineering, QA, and operations.
Rarify and BEYONDXLH
Context
Metabolic-condition platform work and Phase IV longitudinal patient-program execution.
Evidence
Rarify collaborative platform; BEYONDXLH; Crysvita and Dojolvi commercial context; zero-findings audit environment.
Role
Led Rarify platform development; led BEYONDXLH in partnership with Yale School of Medicine and the XLH Network.
PatientStories.ai
Narrative-to-signal platform
Context
Patient-centered engagement and insight platform focused on unstructured experience and longitudinal signal.
Evidence
Current platform design work, stakeholder testing, GLP-1 cohort thinking, and between-visit patient journey modeling.
Role
Founder and designer; developing the platform model, signal logic, and cohort architecture.
GLP-1 and patient journey logic
Context
Patient journeys involving consideration, initiation, persistence, discontinuation, and hidden motivation.
Evidence
Considering / on it / stopped segmentation; hidden motivation and behavior-adjacent use patterns; persistence-focused design.
Role
Designed the cohort logic and patient-experience framework for a GLP-1-oriented learning system.
Timeline
| Period | Program / Platform | Context | Role |
|---|---|---|---|
| 2019–2024 | Ultragenyx Pharmaceutical | Clinical technology, metabolic programs, rare disease, Rarify, BEYONDXLH, Dojolvi-linked Phase III support | Built and led Innovation Lab (~54); led platform and program work |
| 2024–Present | PatientStories.ai | Narrative-to-signal platform; GLP-1 cohort concept; between-visit patient experience | Founder and designer |